Compounds > nicotine
Page last updated: 2024-08-26

nicotine and febuxostat

nicotine has been researched along with febuxostat in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Amer, AE; El-Kashef, HA; El-Sheakh, AR; Hamed, MF; Nader, MA; Shehatou, GSG1

Other Studies

2 other study(ies) available for nicotine and febuxostat

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Febuxostat attenuates vascular calcification induced by vitamin D3 plus nicotine in rats.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2021, Jan-01, Volume: 156

    Topics: Animals; Cholecalciferol; Febuxostat; Humans; Nicotine; Rats; Rats, Sprague-Dawley; Rats, Wistar; Vascular Calcification

2021